<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01073111</url>
  </required_header>
  <id_info>
    <org_study_id>ASSESS</org_study_id>
    <nct_id>NCT01073111</nct_id>
  </id_info>
  <brief_title>Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents</brief_title>
  <acronym>ASSESS</acronym>
  <official_title>Assessment of Neointimal Stent Strut Coverage and Endothelial Function After Second Generation Drug-Eluting Stent Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyogo College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hyogo College of Medicine</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare coronary endothelium function in patients with a
      zotarolimus-eluting versus a sirolimus-eluting or a everolimus-eluting stents with optical
      coherence tomography, vasoconstriction in response to acetylcholine, and coronary biomarker
      level.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare coronary endothelial function after primary angioplasty.</measure>
    <time_frame>6 months and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare the presence of neointimal stent strut coverage via optical coherence tomography.</measure>
    <time_frame>6 months and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare the serum biomarker levels measured in coronary artery blood.</measure>
    <time_frame>6 months and 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>zotarolimus-eluting stents (ENDEAVOR®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sirolimus-eluting stents (CYPHER SELECT® PLUS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>everolimus-eluting stents (PROMUS®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>zotarolimus-eluting stent (ENDEAVOR®)</intervention_name>
    <description>zotarolimus-eluting stent</description>
    <arm_group_label>zotarolimus-eluting stents (ENDEAVOR®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sirolimus-eluting stents (CYPHER SELECT® PLUS)</intervention_name>
    <description>sirolimus-eluting stents</description>
    <arm_group_label>sirolimus-eluting stents (CYPHER SELECT® PLUS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>everolimus-eluting stents (PROMUS®)</intervention_name>
    <description>everolimus-eluting stents</description>
    <arm_group_label>everolimus-eluting stents (PROMUS®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Significant coronary de novo lesion (&gt; 70% by quantitative angiographic analysis)

          -  Patients with stable or acute coronary syndrome considered for coronary
             revascularization

          -  Reference vessel diameter of 2.5 to 3.5 mm by operator assessment

        Exclusion Criteria:

          -  Contraindication to anti-platelet agents

          -  Ostial lesion within 5 mm from ostium

          -  Different DES in other vessel simultaneously

          -  Creatinine level 2.5 mg/dL

          -  Left main stenosis more than 50%.

          -  vein graft lesion

          -  Triple vessel disease with stenosis more than 50% in 3 epicardial coronary arteries

          -  Life expectancy 1 year

          -  Reference vessel &lt; 2.5 mm or &gt; 4.0 mm diameter by visual

          -  Long lesion that require more than three stents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kenichi Fujii</last_name>
    <phone>+81798456553</phone>
    <email>kfujii@hyo-med.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <zip>6638501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2010</study_first_submitted>
  <study_first_submitted_qc>February 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2010</study_first_posted>
  <last_update_submitted>March 18, 2013</last_update_submitted>
  <last_update_submitted_qc>March 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hyogo College of Medicine</investigator_affiliation>
    <investigator_full_name>Kenichi Fujii</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

